Research participation | 5-year survival* | 30-day mortality† | ||||
---|---|---|---|---|---|---|
n | HR | 95% CI | n | OR | 95% CI | |
None (0%) | 63 796 | 1.00 | 43 168 | 1.00 | ||
Low (>0%–5%) | 66 829 | 1.00 | 0.98 to 1.01 | 46 002 | 0.93 | 0.87 to 0.98 |
Medium (>5%–10%) | 42 932 | 1.01 | 0.99 to 1.02 | 29 185 | 0.94 | 0.88 to 1.00 |
High (>10%) | 36 411 | 0.97 | 0.95 to 0.99 | 24 308 | 0.89 | 0.82 to 0.96 |
*Based on 209 968 patients; adjusted for age group, sex, deprivation quintile, Dukes’ stage, tumour site, primary procedure, admission method, screening status, year of diagnosis, annual Trust workload, ECMC status. For the full model results see online supplementary table S2.
†Based on 142 663 patients; adjusted for age group, sex, deprivation quintile, Dukes’ stage, tumour site, admission method, screening status, year of diagnosis, annual Trust workload, ECMC status. For the full model results see online supplementary table S2.
ECMC, Experimental Cancer Medicine Centre.